According to the latest research report by IMARC Group, The global pharmacovigilance and drug safety software market size reached US$ 189.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 283.3 Million by 2028, exhibiting a growth rate (CAGR) of 6.51% during 2023-2028. More Info:- https://www.imarcgroup.com/pharmacovigilance-drug-safety-software-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Pharmacovigilance
and Drug Safety Software
Market Research and
Forecast Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Pharmacovigilance and Drug Safety Software Market Research Report:
The latest report by IMARC, titled “Pharmacovigilance and Drug Safety Software Market: Global
Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” finds that the global
pharmacovigilance and drug safety software market reached a value of US$ 189.9 Million in 2022.
Pharmacovigilance (PV) and drug safety software is a management solution that enables the creation,
classification, review, submission, and maintenance of PV data and adverse event reports. The process
involves monitoring medical drug effects to identify and examine the unfavorable reactions of the
drugs. It creates more knowledge and awareness among healthcare professionals.
PV and drug safety software offers swift science-based safety decisions, ensures global regulatory
compliance, integrates safety and risk management, and lowers the cost of PV procedures. As a result,
the software is extensively employed by pharma and biotech companies, contract research
organizations (CROs), business process outsourcing firms (BPOs), and other PV service providers.
Request Free Sample Report: https://www.imarcgroup.com/pharmacovigilance-drug-safety-
software-market/requestsample

4. Report Description
Report Description and Highlights
Global Pharmacovigilance and Drug Safety Software Market Trends:
The market is primarily driven by the growing adoption of PV and drug safety software by various clinical research
and outsourcing companies. The rising prevalence of chronic diseases, coupled with the increasing incidence rates of
adverse drug reactions (ADRs), are also fueling the growth of the market. In addition to this, the easy adoption of the
software due to the availability of cutting-edge technology is also propelling the market growth. Governments across
various countries are imposing strict regulations for the commercialization of drugs.
Consequently, the growing complexity related to drug safety regulations is also propelling the market growth.
Furthermore, rapid digitization of clinical trials, along with the adoption of advanced technologies that improve
compliance and product safety in PV and drug safety software, is creating a positive outlook for the market. Looking
forward, the market is expected to reach a value of US$ 283.3 Million by 2028, exhibiting a CAGR of 6.51% during the
forecast period (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Breakup by Functionality:
• Adverse Event Reporting Software
• Drug Safety Audits Software
• Issue Tracking Software
• Fully Integrated Software
Breakup by Delivery Mode:
• On-premises
• Cloud-based
Breakup by End User:
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Business Process Outsourcing Firms
• Others
Breakup by Region:

6. Report Description
Report Description and Highlights
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America

7. Report Description
Report Description and Highlights
• Brazil
• Mexico
• Others
• Middle East and Africa

8. Competitive Landscape with Key Players:
• Ab Cube
• Anju Software Inc.
• ArisGlobal LLC
• Cognizant
• Ennov Solutions Inc.
• Extedo GmbH
• Max Application
• Oracle Corporation
• Sarjen Systems Pvt Ltd
• Sparta Systems Inc. (Honeywell International Inc.)
• Tata Consultancy Services Limited
• United BioSource LLC
• Wipro Limited.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/pharmacovigilance-drug-
safety-software-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us